Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014 May;9(5):889-96.
doi: 10.2215/CJN.08350813. Epub 2014 Apr 10.

Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease

Melissa A Cadnapaphornchai  1 , Diana M George, Kim McFann, Wei Wang, Berenice Gitomer, John D Strain, Robert W Schrier
Affiliations
Clinical Trial

Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease

Melissa A Cadnapaphornchai et al. Clin J Am Soc Nephrol. 2014 May.

Abstract

Background and objectives: In autosomal dominant polycystic kidney disease (ADPKD), progressive kidney cyst formation commonly leads to ESRD. Because important manifestations of ADPKD may be evident in childhood, early intervention may have the largest effect on long-term outcome. Statins are known to slow progressive nephropathy in animal models of ADPKD. This randomized double-blind placebo-controlled phase III clinical trial was conducted from 2007 to 2012 to assess the effect of pravastatin on height-corrected total kidney volume (HtTKV) and left ventricular mass index (LVMI) by magnetic resonance imaging (MRI) and urine microalbumin excretion (UAE) in children and young adults with ADPKD.

Designs, setting, participants, & measurements: There were 110 pediatric participants with ADPKD and normal kidney function receiving lisinopril who were randomized to treatment with pravastatin or placebo for a 3-year period with evaluation at 0, 18, and 36 months. The primary outcome variable was a ≥ 20% change in HtTKV, LVMI, or UAE over the study period.

Results: Ninety-one participants completed the 3-year study (83%). Fewer participants receiving pravastatin achieved the primary endpoint compared with participants receiving placebo (69% versus 88%; P=0.03). This was due primarily to a lower proportion reaching the increase in HtTKV (46% versus 68%; P=0.03), with similar findings observed between study groups for LVMI (25% versus 38%; P=0.18) and UAE (47% versus 39%; P=0.50). The percent change in HtTKV adjusted for age, sex, and hypertension status over the 3-year period was significantly decreased with pravastatin (23% ± 3% versus 31% ± 3%; P=0.02).

Conclusions: Pravastatin is an effective agent to slow progression of structural kidney disease in children and young adults with ADPKD. These findings support a role for early intervention with pravastatin in this condition.

Keywords: children; kidney volume; polycystic kidney disease; statins.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Course of study participants. A total of 111 potential participants were screened, including 110 participants who were randomly assigned in a double-blind manner to receive either pravastatin or placebo. A total of 91 participants (83%) completed the 3-year trial. CK, creatine kinase.
Figure 2.
Figure 2.
Study endpoints. The primary end point was the percent of participants demonstrating ≥20% increase over the three-year study period in any of the total kidney volume corrected for height (HtTKV), left ventricular mass index (LVMI), or urine microalbumin excretion (UAE) between pravastatin and placebo study groups. Secondary end points included ≥20% increase in these individual variables.
Figure 3.
Figure 3.
Percent increase in HtTKV over the course of the study.
Figure 4.
Figure 4.
Effect of pravastatin on change in HtTKV.
See this image and copyright information in PMC

Comment in

  • 831–836

References

    1. Somlo S, Chapman AB: Autosomal dominant polycystic kidney disease. In: Schrier's Diseases of the Kidney, edited by Coffman TM, Falk RJ, Molitoris BA, Neilson EG, Schrier RW, 9th Ed., Philadelphia, Lippincott Williams & Wilkins, 2012, pp 519–563
    1. MacDermot KD, Saggar-Malik AK, Economides DL, Jeffery S: Prenatal diagnosis of autosomal dominant polycystic kidney disease (PKD1) presenting in utero and prognosis for very early onset disease. J Med Genet 35: 13–16, 1998 - PMC - PubMed
    1. Pretorius DH, Lee ME, Manco-Johnson ML, Weingast GR, Sedman AB, Gabow PA: Diagnosis of autosomal dominant polycystic kidney disease in utero and in the young infant. J Ultrasound Med 6: 249–255, 1987 - PubMed
    1. Cadnapaphornchai MA, McFann K, Strain JD, Masoumi A, Schrier RW: Prospective change in renal volume and function in children with ADPKD. Clin J Am Soc Nephrol 4: 820–829, 2009 - PMC - PubMed
    1. Hafez KS, Inman SR, Stowe NT, Novick AC: Renal hemodynamic effects of lovastatin in a renal ablation model. Urology 48: 862–867, 1996 - PubMed

Publication types

MeSH terms